KalVista Pharmaceuticals, Inc. (KALV)

KalVista Pharmaceuticals' stock has been influenced by several key events over the past six months. A strong EKTERLY launch and revenue update led to a 14% increase in shares after hours. EKTERLY's approval in Japan was announced. The company's Q3 2025 earnings beat analysts' expectations. Analyst ratings in November 2025 maintained a positive outlook, with an average one-year price target suggesting a significant upside. The company reported a Q1 2025 revenue miss. The stock has shown a positive trend over the past year, with a 48.45% increase.

Demand for KalVista Pharmaceuticals' products, particularly EKTERLY, has shown some effects from seasonal variability. Prescription refills surpassed initial prescriptions in the fourth quarter of 2025, with some activity potentially reflecting demand pulled forward ahead of the holidays. The company anticipates a decline in sales for the first quarter due to typical seasonal factors related to insurance reauthorizations. Fundamental demand for EKTERLY has remained strong.

KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing small molecule protease inhibitors. The company targets diseases with unmet medical needs, particularly in the pharmaceutical, biotechnology, and life sciences sectors, with a focus on selective inhibition of plasma kallikrein for disorders involving vascular leak, edema, and inflammation. Its product portfolio includes EKTERLY (sebetralstat), an oral on-demand therapy for HAE attacks, a Factor XIIa inhibitor in preclinical phase, KVD001 which completed Phase II clinical trial for DME treatment, KVD900 which completed Phase II clinical trial for acute HAE attacks, and KVD824, an oral product candidate for HAE treatment.

KalVista Pharmaceuticals is headquartered in Cambridge, Massachusetts, with operations in the United Kingdom, Utah, and Switzerland. EKTERLY has been commercially launched in the U.S. and has seen strong early adoption in Germany. The company has partnered with Multicare Pharma to commercialize sebetralstat in Latin America and plans to expand into other major markets in 2026.

KalVista Pharmaceuticals' brand reputation has been largely positive, driven by progress in clinical programs and the commercial launch of EKTERLY. The approval of EKTERLY in Japan and its U.S. commercial launch have boosted the company's profile. Analyst confidence is reflected in consensus "Strong Buy" ratings and high price targets. The company's focus on unmet needs in rare diseases contributes to a positive reputation. KalVista competes with other pharmaceutical companies in the oral HAE market.

KalVista Pharmaceuticals' ownership is mainly held by institutional investors, with 257 owners holding a total of 65,170,768 shares. Major institutional owners include VR Adviser, LLC, Tang Capital Management Llc, Frazier Life Sciences Management, L.P., Suvretta Capital Management, Llc, Capital World Investors, BlackRock, Inc., and Vanguard Group Inc. Individual ownership by insiders ranges from high single digits to low teens collectively, with insiders selling more stock than they have bought in the past three months.